New Paper- Intranasal VIP safely restores volume to multiple grey matter nuclei in patients with CIRS

Abstract:

Evidence has accumulated since 2008 that intranasal, topical application of vasoactive intestinal polypeptide (VIP) can be administered safely to patients with a multi-system, multisymptom illness, called chronic inflammatory response syndrome (CIRS), acquired following exposure to biologically produced toxins and inflammagens. To date, over 300 physicians have prescribed intranasal VIP for their CIRS patients; these physicians have overwhelmingly (>90%) reported intranasal VIP to reduce symptoms; reduce elevated levels of MMP9, TGF beta-1 and C4a; raise low levels of VEGF; normalize clotting abnormalities, including acquired von Willebrand’s; and return regulation to pituitary systemic axes involving ACTH/cortisol and ADH/osmolality. These changes did not occur without use of VIP, though antecedent steps in a sequential treatment protocol provided benefit for many patients. The mechanism of these salutary health effects provided by VIP likely involves correction of abnormalities in ribosomal gene activation, nuclear encoded mitochondrial gene activation and an upregulation of Ikaros, a zinc fingered transcription factor. Recent preliminary work using sequential measurement of CNS volumes by NeuroQuant showed a longer treatment window (> 12 weeks) and higher doses of VIP (> 6 doses/day) safely corrected multinuclear atrophy of grey matter. The current study built upon this preliminary work and identified a course of VIP treatment that restores grey matter nuclear atrophy in CIRS patients. Safety of VIP and durability of benefit were both shown with no significant adverse effects reported by any patients.

Read the rest of this paper here!

Featured Resources

NEW FEATURED ARTICLE Actinobacteria Update: The revolutionary findings on biotoxin illness further explained.

Based on newer, published and confirmed information and testing, we’ve been able to expand the concept of specific causation of "mold illness" or CIRS to include indoor-dwelling Actinobacteria

A Physician’s Guide to Use of Actinobacteria Indices

In the newest report from EnviroBiomics, Actinomycetales, also called Actinobacteria, are now reported with an additional factor called an Actino Index. We look at a Dominance Index (DI) and a Prevalence Index (PI) to assist physicians in making clinical de...

New Research Article!

Treatable metabolic and inflammatory abnormalities in Post COVID Syndrome (PCS) define the transcriptomic basis for persistent symptoms: Lessons from CIRS

Newer Molecular Methods Bring New Insights into Human- And BuildingHealth Risk Assessments from Water-Damaged Buildings: Defining Exposure and Reactivity, the Two Sides of Causation of CIRS-WDB Illness

Scientific disciplines dependent on accurate analytics invariably evolve due to advances in technical aspects of measurement. In disciplines in which adequate measurement is not available for applications to public health policy, the impact of new paradigms...

Metabolism, molecular hypometabolism and inflammation: Complications of proliferative physiology include metabolic acidosis, pulmonary hypertension, T reg cell deficiency, insulin resistance and neuronal injury

Dr. Shoemaker’s latest academic paper is published. This paper, though technical, reports the metabolic basis of conditions routinely found in CIRS.